Welcome to our dedicated page for Celcuity SEC filings (Ticker: CELC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Celcuity Inc means dissecting dense disclosures on trial endpoints, R&D burn, and licensing terms—details that can span hundreds of pages. If you have ever wondered where to locate the latest Celcuity quarterly earnings report 10-Q filing or how to decode a 300-page 10-K, you are not alone.
Stock Titan’s AI engine digests every sentence the moment it hits EDGAR, then delivers concise explanations in plain English. The result: Celcuity SEC filings explained simply. Whether you need understanding Celcuity SEC documents with AI or instant alerts on Celcuity Form 4 insider transactions real-time, our platform turns regulatory text into actionable context.
- 10-K: Get the Celcuity annual report 10-K simplified—clinical pipeline progress, cash runway, and risk factors, all summarized.
- 10-Q: Compare quarter-over-quarter R&D spend with automated charts and Celcuity earnings report filing analysis.
- 8-K: Stay ahead with Celcuity 8-K material events explained—from Phase 3 data releases to financing rounds.
- Form 4: Monitor Celcuity insider trading Form 4 transactions and track each Celcuity executive stock transactions Form 4 in real time.
- DEF 14A: Review the Celcuity proxy statement executive compensation section with AI-highlighted pay metrics.
Every filing is updated the moment Celcuity submits it, complete with AI-powered summaries, key-metric extractions, and side-by-side document comparisons. Skip the biotech jargon, save hours of manual reading, and focus on the insights that move Celcuity’s valuation.
Celcuity Inc. (CELC) filed an 8-K detailing several capital-raising and financing actions dated 28 Jul 2025.
Loan amendment: The company executed a Second Amendment to its Amended & Restated Loan and Security Agreement with Innovatus and Oxford Finance. Key changes: (i) allows issuance of $150 m aggregate principal Convertible Senior Notes due 2031 and related capped-call transactions; (ii) permits equity conversion of the notes solely into common shares (cash only for fractional shares); (iii) requires a one-time $25 k amendment fee paid to Oxford; and (iv) extends to 9 May 2026 Innovatus’ option to convert up to 20 % of Term A principal into CELC stock at $10.00 per share.
Capital markets activity: Celcuity launched a concurrent offering for $150 m of the Notes plus $75 m of common stock. Proceeds would strengthen liquidity and fund operations.
Additional debt capacity: Management believes the Phase 3 VIKTORIA-1 data achieve the “Term D Milestone,” enabling a $30 m Term D Loan draw by 31 Aug 2025.
Preliminary cash position: Cash, equivalents and short-term investments are expected at ~<$168.4 m> on 30 Jun 2025 versus $283.1 m a year earlier (-41 %). Figures are unaudited and subject to change.
Forward-looking statements caution that the offerings may not close, the Term D draw might not occur, and final June-quarter financials could differ.
Celcuity Inc. (CELC) filed a Form 144 indicating an intention to sell up to 100,000 common shares through RBC Capital Markets on or about 28 Jul 2025. At the filing’s reference price, the shares have an aggregate market value of $4.398 million and represent roughly 0.3 % of the 37.87 million shares outstanding.
The shares were originally acquired on 28 Feb 2014 via an investment transaction paid by check. The filer reports no sales of Celcuity securities in the past three months. The notice states that the seller is unaware of any undisclosed material adverse information and affirms compliance with Rule 10b5-1 if applicable. The planned sale will take place on the NASDAQ exchange. No additional financial data, earnings information, or prior insider transactions are disclosed in this filing.
Celcuity Inc. (NASDAQ: CELC) filed a Form 144 indicating the intent to sell 9,325 common shares, valued at roughly $420,766 based on the market price when the form was prepared. The shares, which equal about 0.02 % of the 37.9 million shares outstanding, were acquired through two stock-grant awards on 05/14/2022 (7,843 sh) and 05/12/2021 (1,482 sh). No cash consideration was paid for the grants.
The proposed sale is expected on or after 07/28/2025 through broker RBC Capital Markets, with execution on the NASDAQ market. The filer reported no other sales during the past three months and affirmed they possess no undisclosed material adverse information about the company. Form 144 is a notice only; execution is not guaranteed and volume limits under Rule 144 apply.
Given the modest size relative to CELC’s float and the routine nature of insider liquidity events, the filing is unlikely to be material for investors unless accompanied by additional insider activity or negative corporate developments.
FAQ
What is the current stock price of Celcuity (CELC)?
What is the market cap of Celcuity (CELC)?
